Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma.

Authors:
Yueqiang Song
Yueqiang Song
Center of Reproductive Medicine
Donglai Chen
Donglai Chen
2012 Clinical Medicine
Xi Zhang
Xi Zhang
Xinqiao Hospital
China
Yuping Luo
Yuping Luo
Nanchang University
China
Siguang Li
Siguang Li
Nanchang University
China

Thorac Cancer 2019 May 16;10(5):1220-1228. Epub 2019 Apr 16.

Stem Cell Translational Research Center, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Background: Lung adenocarcinoma (LUAD) is a set of heterogeneous diseases with distinct genetic and transcriptomic characteristics. Since the introduction of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society histologic classification, increasing evidence has provided insights into genomic mutations and rearrangements among individual histologic subtypes of LUAD. However, how genotypic and phenotypic features of LUAD are interconnected is not well understood.

Methods: We obtained the genomic, transcriptomic, and clinical data sets of 488 LUAD patients from The Cancer Genome Atlas database. Advanced statistical models were used to disentangle the interactions between genetic mutations and expression profiles, and to assess the alterations and changes in expression of each histologic subtype. The prognostic impacts of genetic mutations, expression profiles, and clinicopathological features were integrated to predict the outcomes of LUAD patients.

Results: From our data, one or more genetic mutations correlate with expression levels of 6054/18175 (33.3%) genes and explain 8-40% of observed variability in LUAD. The genetic mutations and expression profiles varied remarkably among the histologic subtypes of LUAD, which helped to explain the different prognostic impact based on subtype classification. Genomic, transcriptomic, and clinical data were all shown to have utility for predicting overall and recurrence-free survival, with the largest contribution from the transcriptome.

Conclusion: Our prediction model integrating genetic mutations, expression profiles, and clinicopathological features exhibited superior accuracy over the current tumor node metastasis staging system to prognosticate outcomes of patients with LUAD (overall survival 67% vs. 55%, recurrence-free survival 57% vs. 49%; Pā€‰<ā€‰0.01).

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13072DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501026PMC
May 2019

Article Mentions


Provided by Crossref Event Data
twitter
Twitter:
April 26, 2019, 4:57 am EST

Publication Analysis

Top Keywords

genetic mutations
24
expression profiles
20
mutations expression
20
subtypes luad
8
genomic transcriptomic
8
lung adenocarcinoma
8
profiles clinicopathological
8
luad
8
clinicopathological features
8
histologic subtypes
8
transcriptomic clinical
8
integrating genetic
8
clinical data
8
recurrence-free survival
8
mutations
7
expression
7
genetic
6
profiles
5
predict outcomes
4
integrated predict
4

References

(Supplied by CrossRef)

Similar Publications